2.Preserving the natural shape of the tragus and the pretragal depression during making cartilage perichondrium composite graft in tympanoplasty.
Hou-En LI ; Jian-Jun SUN ; Yong-Sheng LIN
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2007;42(2):152-153
Adult
;
Cartilage
;
surgery
;
Cholesteatoma, Middle Ear
;
surgery
;
Ear Auricle
;
surgery
;
Esthetics
;
Female
;
Humans
;
Male
;
Middle Aged
;
Otitis Media, Suppurative
;
surgery
;
Tympanoplasty
;
methods
4.Influences of perindopril on pulmonary vascular remodeling in normobaric hypoxia-hypercapnia rats
Peng-Lin YANG ; Lin-Sheng YU ; Yong-Sheng GONG ; Lu-Zhen ZHENG ; Wei WANG ; Liang-Gang HU ;
Chinese Journal of Clinical Pharmacology and Therapeutics 1999;0(04):-
Aim To investigate the effects of perindopril, an angiotensin converting enzyme inhibitor, on mean pulmonary arterial pressure(mPAP) and pulmonary vascular remodeling.Methods Using the normobaric hypoxia-hypercapnia rat model,the changes of plasma angiotensin Ⅱ (Ang Ⅱ), mPAP and ultrastructure of pulmonary arteriolar wall were observed after administration of perindopril.Results The mPAP and AngⅡ were significantly greater and the ultrastructure of the small lung vessels had a more obvious change in the 4 weeks hypoxia-hypercapnia group than those in the control group.It was also found that perindopril decreased AngⅡ, declined mPAP and ameliorated vascular ultrastructure change.But the change of ultrastructure was similar in the 8 weeks hypoxia-hypercapnia group and perindopril treatment group.Conclusion It is suggested that chronic hypoxia-hypercapnia should induce the remodeling of pulmonary arteriolar structure via AngⅡ and that perindopril could ease pulmonary vascular remodeling in early stage.
5.Effect of nourishing Yin, strengthening Qi and activating blood decoction on Fas/FasL in salivary glands of NOD mice with Sjogren's syndrome and their mRNA expression.
Guo-Lin WU ; Tian-Yi LI ; Wen-Wen LU ; Guo-You YU ; Yong-Sheng FAN
China Journal of Chinese Materia Medica 2013;38(23):4148-4151
OBJECTIVETo observe the effect of nourishing Yin, strengthening Qi and activating blood decoction on Fas/FasL in salivary glands of NOD mice with Sjogren's syndrome and their mRNA expression.
METHODThirty-two NOD mice were randomly divided into the model group, the traditional Chinese medicine group (TCM group, orally given 0.4 mL nourishing Yin, strengthening Qi and activating blood decoction as per 100 g x kg(-1) everyday), the hydroxychloroquine group (given 0.4 mL hydroxychloroquine as per 60 mg x kg(-1) everyday), the traditional Chinese medicine and western medicine group (TCM WM group, given nourishing Yin, Strengthening Qi and activating blood decoction 50 g x kg(-1) and hydroxychloroquine 60 mg x kg(-1), 0.4 mL everyday), with eight mice in each group. Eight Balb/C mice were selected as the normal control group (normal group). All of mice were killed after eight weeks, and their submaxillary glands were dissected. The expression levels of Fas/FasL were examined by immunohistochemical method, and the FasL mRNA was detected by RT-PCR.
RESULTThe expression levels of Fas/FasL in salivary glands of the model group were higher than that of other groups (P < 0.05). The expression level of FasL of the normal group was much lower than that in the hydroxychloroquine group (P < 0.05). The relative expression level of Fas mRNA in salivary glands of the model group was higher than that in other groups, but the control group was notably lower than other groups (P < 0.05). The expression level of FasL mRNA in salivary glands of the model group was higher than that in TCM and TCM WM groups (P < 0.05). But the expression level in TCM WM group was notably lower than the hydroxychloroquine group (P < 0.05).
CONCLUSIONThe nourishing Yin, strengthening Qi and activating blood decoction could down-regulate the expression level of Fas/FasL in salivary glands of NOD mice with Sjogren's syndrome and their mRNA expression, and had a better efficacy after being combined with hydroxychloroquine. The nourishing Yin, strengthening Qi and activating blood decoction might treat the Sjogren's Syndrome by reducing apoptosis which is regulated by Fas/FasL
Animals ; Fas Ligand Protein ; genetics ; Female ; Gene Expression Regulation ; Medicine, Chinese Traditional ; methods ; Mice ; Mice, Inbred NOD ; Qi ; RNA, Messenger ; genetics ; metabolism ; Salivary Glands ; metabolism ; Sjogren's Syndrome ; blood ; genetics ; therapy ; Yin-Yang ; fas Receptor ; genetics
6.Lateral supramalleolar artery descending branch antidromic flap for the repair of soft tissue defects in the foot and ankle.
Yong-Dong ZHU ; Mao-Lin TAN ; Shao-Jie LI ; Sheng-Chun QIU
China Journal of Orthopaedics and Traumatology 2014;27(3):258-260
OBJECTIVETo evaluate the effect of lateral supramalleolar artery descending branch antidromic flap for the repair of soft tissue defects in the foot and ankle.
METHODSFrom May 2009 to October 2013,12 patients with soft tissue defects combined with tendon and bone exposure in the foot and ankle were treated by lateral supramalleolar artery descending branch antidromic flap for the repair of soft tissue defects in the foot and ankle, including 9 males and 3 females with an average age of 37.5 years old ranging from 19 to 58 years. Ten cases had the soft tissue defects in the dorsum of foot and 2 in the ankle. The defect area of soft tissue was from 11 cm x 9 cm to 8 cm x 5 cm.
RESULTSTwelve patients were follow-up for 3 to 12 months (averaged 7.3 months). The flaps of 9 cases were survived,the flaps edges of the other 3 cases were necrosis,and healed after dressing change. The flaps were slightly swelling without ulcer occurrence.
CONCLUSIONLateral supramalleolar artery descending branch antidromic flap can repairing the damage by one-stage operation with advantage of dissection easy,rich blood supply without sacrifice of major artery.
Adult ; Ankle ; blood supply ; surgery ; Arteries ; surgery ; Female ; Foot ; blood supply ; surgery ; Foot Injuries ; surgery ; Humans ; Male ; Middle Aged ; Soft Tissue Injuries ; surgery ; Surgical Flaps ; Young Adult
7.Ribozyme riboswitch based gene expression regulation systems for gene therapy applications: progress and challenges.
Jing-Xian FENG ; Jia-wen WANG ; Jun-sheng LIN ; Yong DIAO
Acta Pharmaceutica Sinica 2014;49(11):1504-1511
Robust and efficient control of therapeutic gene expression is needed for timing and dosing of gene therapy drugs in clinical applications. Ribozyme riboswitch provides a promising building block for ligand-controlled gene-regulatory system, based on its property that exhibits tunable gene regulation, design modularity, and target specificity. Ribozyme riboswitch can be used in various gene delivery vectors. In recent years, there have been breakthroughs in extending ribozyme riboswitch's application from gene-expression control to cellular function and fate control. High throughput screening platforms were established, that allow not only rapid optimization of ribozyme riboswitch in a microbial host, but also straightforward transfer of selected devices exhibiting desired activities to mammalian cell lines in a predictable manner. Mathematical models were employed successfully to explore the performance of ribozyme riboswitch quantitively and its rational design predictably. However, to progress toward gene therapy relevant applications, both precision rational design of regulatory circuits and the biocompatibility of regulatory ligand are still of crucial importance.
Animals
;
Cell Line
;
Gene Expression
;
Gene Expression Regulation
;
Genetic Therapy
;
Humans
;
Ligands
;
Models, Theoretical
;
RNA, Catalytic
;
genetics
;
Riboswitch
;
genetics
8.Mechanism of tanshinone II A in inhibiting transformation of aortic valvular myofibroblast to osteoblast-like phenotype.
Ying-nian SHEN ; Wei-lin HU ; Zheng-ping CHEN ; Li CAI ; Yong-sheng LI
China Journal of Chinese Materia Medica 2015;40(18):3636-3643
Aortic valve calcification (AVC) is a pathological process correlated with multiple disease causes and actively regulated by cardiac valve cells. In this study, porcine aortic valve myofibroblasts cultured in vitro were treated with 50 μg z L(-1) of pathological factor tumor necrosis factor α (TNF-α). Tanshinone II A (TSN) with the concentration of 50 mg x L(-1) and TNF-α were combined in incubating cells for 72 h (3 d) and 120 h (5 d). The Western blotting and Real-time PCR were adopted to detect the changes in smooth muscle α actin (α-SMA), bone morphogenetic protein 2 ( BMP2), alkaline phosphatase (ALP) in cells, and expressions of key effect proteins GSK-3β and β-catenin on Wnt/β-catenin signal pathway. According to the findings, TNF-α can significantly increase the expression of myofibroblasts α-SMA and add the transformation activity to them, with nearly no expression of BMP2, ALP and mRNA in the control group and the TSN group but significant increase in their expressions in the TNF-α group (P < 0.01), which showed osteoblast-like phenotype. Moreover, TNF-α down-regulated the expression of up-streaming regulator GSK-3β and mRNA expression (P < 0. 01) , notably increased the expression of key effect protein β-catenin, but with no significant difference in mRNA with the control group and the TSN group. The result demonstrated that TSN showed a certain inhibitory effect on TNF-α's pathological impact (P < 0.05) in a time-dependent manner. Inflammatory factor TNF-α may promote the transformation of aortic valvular myofibroblasts to osteoblast-like phenotype by activating Wnt/β-catenin signal pathway in aortic valvular myofibroblasts, so as to cause AVC. Tanshinone II A can have a preventive effect in AVC by activating GSK-3β proteins and regulating signal transduction of Wnt/β-catenin signal pathway.
Animals
;
Aortic Valve
;
cytology
;
drug effects
;
metabolism
;
Cells, Cultured
;
Diterpenes, Abietane
;
pharmacology
;
Drugs, Chinese Herbal
;
pharmacology
;
Glycogen Synthase Kinase 3
;
genetics
;
metabolism
;
Glycogen Synthase Kinase 3 beta
;
Myofibroblasts
;
cytology
;
drug effects
;
metabolism
;
Osteoblasts
;
cytology
;
drug effects
;
metabolism
;
Swine
;
Tumor Necrosis Factor-alpha
;
genetics
;
metabolism
;
beta Catenin
;
genetics
;
metabolism
9.The molecular design and drug development of recombinant long-acting follicle stimulating hormone.
Acta Pharmaceutica Sinica 2012;47(4):421-426
Follicle-stimulating hormone (FSH) is a glycoprotein which regulates the development, growth, pubertal maturation and reproductive processes of the body. Exogenous FSH has been used to promote ovarian follicular growth and maturation in female and spermatogenesis in male. The relative short elimination half life and rapid metabolic clearance of current versions of FSH require a daily or twice-daily scheduled subcutaneous injection to maintain stable FSH level being not below the threshold during ovarian stimulation. The development of recombinant long-acting FSH with enhanced biological activities may be helpful for less injection therefore to improve patient compliance, while reducing patient stress and error rates. A number of technological strategies have been explored to develop recombinant longer-acting FSH. For examples, attachment of the C-terminal peptide (CTP) of the human chorionic gonadotropin beta subunit or a sequence containing potential glycosylation sites to either subunit of FSH, creation of a single chain containing the alpha and beta subunits of FSH combined with CTP or N-linked glycosylation signal sequence as a linker, or fusion of the Fc domain of IgGi to FSH. Based on the modifiable molecular structure and pharmacokinetic and pharmacodynamic properties of recombinant FSH, it is hopeful that more FSH drugs with prolonged half-life and increased bioactivity will be developed to meet the modern clinical demands.
Animals
;
Follicle Stimulating Hormone, Human
;
chemistry
;
genetics
;
metabolism
;
pharmacology
;
Glycosylation
;
Half-Life
;
Humans
;
Immunoglobulin Fc Fragments
;
chemistry
;
metabolism
;
Ovulation Induction
;
methods
;
Receptors, FSH
;
chemistry
;
metabolism
;
Recombinant Fusion Proteins
;
chemistry
;
genetics
;
metabolism
;
pharmacology
;
Reproduction
;
drug effects
10.Combination of taurine with silybin meglumine in treatment of patients with non-alcohlic steatohepatitis
Xin ZENG ; Yong LIN ; Xia SHENG ; Yiping WANG ; Yuexiang CHEN ; Weifen XIE ; Weizhong CHEN
Chinese Journal of Digestion 2010;30(7):441-443
Objective To evaluate the therapeutic effects of taurine combined with silybin meglumine in patients with non-alcoholic steatohepatitis (NASH). Methods One hundred patients with NASH were divided into two groups with 50 for each. The patients in the control group received polyene phosphatidyl choline (456 mg) combined with silybin meglumine (100 mg) 3 times daily for 24 weeks. While those in the treatment group received taurine (2 g) combined with silybin meglumine (100 mg) 3 times daily for 24 weeks. All patients were asked to take up basic therapy including drinking without alcohol, restricting sugary and fatty intake, improving food structure, carrying moderate aerobics and lightening body weight. Results At the end of 24 weeks, the clinical symptoms and the liver function ameliorated in two groups. Ultrasonic or CT examination showed that the steatohepatitits was improved significantly in two groups. Additionally, the levels of blood glucose, serum triglyceride and cholesterol as well as BMI decreased simultaneously (all P value <0. 05). Whereas the treatment group was superior to control group in aspect of amelioration of inappetite, nausea and vomiting as well as lever of serum triglyceride (all P value <0. 05). There was no side effect in the treatment group. Conclusion Based on the basic therapy, taurine combined with silybin meglumine can mitigate the degree of NASH, improve the metabolism of blood glucose and lipid with few side-effects.